Profile data is unavailable for this security.
About the company
Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. It is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.
- Revenue in USD (TTM)31.41k
- Net income in USD-37.28m
- Incorporated2014
- Employees57.00
- LocationEyenovia Inc295 Madison Ave Ste 2400NEW YORK 10017United StatesUSA
- Phone+1 (813) 766-9539
- Fax+1 (302) 636-5454
- Websitehttps://eyenovia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioXcel Therapeutics Inc | 2.40m | -107.83m | 25.96m | 74.00 | -- | -- | -- | 10.80 | -3.56 | -3.56 | 0.074 | -1.84 | 0.0234 | 0.5941 | 3.87 | 32,472.97 | -104.93 | -74.57 | -150.29 | -84.06 | 43.07 | -- | -4,487.39 | -32,300.74 | 2.25 | -10.10 | 3.59 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| KALA BIO Inc | 0.00 | -38.72m | 26.72m | 43.00 | -- | 1.94 | -- | -- | -13.95 | -13.95 | 0.00 | 2.98 | 0.00 | -- | -- | 0.00 | -60.45 | -57.83 | -78.16 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -11.36 | 0.7174 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
| Acasti Pharma Inc | 0.00 | -11.45m | 27.58m | 32.00 | -- | 0.4646 | -- | -- | -1.22 | -1.22 | 0.00 | 5.85 | 0.00 | -- | -- | -- | -16.04 | -31.68 | -16.57 | -33.95 | -- | -- | -- | -56,271.43 | -- | -37.80 | 0.00 | -- | -- | -- | 69.71 | -- | -47.16 | -- |
| Dare Bioscience Inc | 2.84m | -7.20m | 27.60m | 23.00 | -- | 10.33 | -- | 9.72 | -1.07 | -1.07 | 0.3579 | 0.3126 | 0.1213 | -- | 3.85 | 123,462.20 | -30.76 | -109.51 | -191.39 | -246.26 | 0.8477 | -- | -253.60 | -1,104.55 | -- | -- | 0.00 | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| Incannex Healthcare Inc | -100.00bn | -100.00bn | 29.21m | -- | -- | 2.07 | -- | -- | -- | -- | -- | 0.8907 | -- | -- | -- | -- | -- | -54.94 | -- | -59.47 | -- | -- | -- | -1,033.07 | -- | -- | 0.00 | -- | 61.92 | 3.38 | -24.35 | -- | 54.12 | -- |
| Equillium Inc | 42.62m | -8.32m | 30.11m | 45.00 | -- | 1.34 | -- | 0.7064 | -0.2377 | -0.2377 | 1.20 | 0.6333 | 0.8388 | -- | 8.85 | 968,704.60 | -16.37 | -46.81 | -29.58 | -57.36 | -- | -- | -19.52 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
| Ocuphire Pharma Inc | 16.45m | -14.11m | 34.84m | 14.00 | -- | 0.8503 | -- | 2.12 | -0.5507 | -0.5507 | 0.6871 | 1.56 | 0.3726 | -- | 6.53 | 1,174,929.00 | -31.95 | -58.31 | -36.01 | -65.94 | -- | -- | -85.75 | -137.92 | -- | -10.80 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| Eyenovia Inc | 31.41k | -37.28m | 38.49m | 57.00 | -- | -- | -- | 1,225.34 | -0.7897 | -0.7897 | 0.0007 | -0.0425 | 0.0013 | -- | 0.0418 | 551.05 | -154.24 | -80.31 | -262.28 | -117.70 | -1,489.11 | -- | -118,693.60 | -680.95 | 0.267 | -40.92 | 1.20 | -- | -- | -- | 2.68 | -- | 152.20 | -- |
| Natural Alternatives International, Inc. | 120.20m | -3.31m | 39.87m | 317.00 | -- | 0.4741 | 29.71 | 0.3317 | -0.5646 | -0.5646 | 20.53 | 13.56 | 0.8091 | 3.63 | 12.77 | 379,183.00 | -2.23 | 4.90 | -2.56 | 5.93 | 8.85 | 15.98 | -2.75 | 3.80 | 2.44 | -2.71 | 0.0996 | 0.00 | -9.91 | 3.06 | -76.46 | -20.74 | 27.08 | -- |
| Fortress Biotech Inc | 82.62m | -49.54m | 43.80m | 186.00 | -- | 2.43 | -- | 0.5302 | -3.71 | -3.71 | 6.05 | 0.7915 | 0.5063 | 2.36 | 6.07 | 444,215.10 | -65.90 | -52.50 | -113.69 | -99.46 | 68.77 | 63.17 | -130.17 | -236.94 | 1.24 | -13.40 | 1.26 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
| Aadi Bioscience Inc | 23.82m | -65.44m | 46.03m | 70.00 | -- | 0.5842 | -- | 1.93 | -2.43 | -2.43 | 0.8829 | 3.20 | 0.1884 | 0.6393 | 4.96 | 267,606.80 | -51.76 | -50.25 | -60.12 | -56.15 | 87.18 | -- | -274.77 | -473.97 | 3.92 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
| Immix Biopharma Inc | 0.00 | -19.02m | 48.86m | 14.00 | -- | 2.04 | -- | -- | -0.8411 | -0.8411 | 0.00 | 0.871 | 0.00 | -- | -- | 0.00 | -86.64 | -- | -100.82 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
| Odonate Inc | 0.00 | -102.07m | 50.02m | 137.00 | -- | 1,844.41 | -- | -- | -13.59 | -13.59 | 0.00 | 9.27 | 0.00 | -- | -- | 0.00 | -66.98 | -58.36 | -83.00 | -65.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | -- | -- |
| Lexaria Bioscience Corp | 411.01k | -4.85m | 50.91m | 5.00 | -- | 5.03 | -- | 123.86 | -0.4455 | -0.4455 | 0.0408 | 0.6403 | 0.0539 | -- | 2.16 | 82,202.00 | -63.85 | -95.67 | -65.93 | -96.58 | 98.83 | 76.98 | -1,185.15 | -1,612.76 | -- | -64.96 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
Data as of Sep 19 2024. Currency figures normalised to Eyenovia Inc's reporting currency: US Dollar USD
13.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Jun 2024 | 6.06m | 7.88% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.87m | 2.44% |
| Avenue Capital Management II LPas of 30 Jun 2024 | 547.81k | 0.71% |
| Geode Capital Management LLCas of 30 Jun 2024 | 408.52k | 0.53% |
| Millennium Management LLCas of 30 Jun 2024 | 393.17k | 0.51% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Jun 2024 | 362.18k | 0.47% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 250.95k | 0.33% |
| Jane Street Capital LLCas of 30 Jun 2024 | 228.51k | 0.30% |
| SkyView Investment Advisors LLCas of 30 Jun 2024 | 146.07k | 0.19% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 124.61k | 0.16% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
